Marek Wardęcki
About
Marek Wardęcki is a scholar working on Hematology, Endocrinology, Diabetes and Metabolism and Physiology.
According to data from OpenAlex, Marek Wardęcki has authored 25 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 11 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Physiology. Recurrent topics in Marek Wardęcki's work include Blood groups and transfusion (14 papers), Diabetes Management and Research (11 papers) and Erythrocyte Function and Pathophysiology (8 papers). Marek Wardęcki is often cited by papers focused on Blood groups and transfusion (14 papers), Diabetes Management and Research (11 papers) and Erythrocyte Function and Pathophysiology (8 papers). Marek Wardęcki collaborates with scholars based in United States, France and United Kingdom. Marek Wardęcki's co-authors include Matthew C. Riddle, Richard M. Bergenstal, Isabel Muehlen-Bartmer, M. Ziemen, Hannele Yki‐Järvinen, Emmanuelle Boëlle, Geremia B. Bolli, H Yki-Järvinen, Philip Home and Riccardo Perfetti and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Diabetes Care.
In The Last Decade
Marek Wardęcki
25 papers receiving 675 citations
Peers
Marek Wardęcki
Anna Zaremba Denmark
Laura Guazzarotti Italy
Kuralay Atageldiyeva Kazakhstan
B. Augendre‐Ferrante France
C. S. Paththinige Sri Lanka
Aldo Del Col Canada
Blaž Krhin Slovenia
Richard Dolinar United States
Heinrich Kahles Germany
Jeanne E. O’Brien United States
Citations per year, relative to Marek Wardęcki Marek Wardęcki (= 1×)
peers
Anna Zaremba
Countries citing papers authored by Marek Wardęcki
Since
Specialization
Citations
This map shows the geographic impact of Marek Wardęcki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marek Wardęcki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marek Wardęcki more than expected).
Fields of papers citing papers by Marek Wardęcki
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marek Wardęcki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marek Wardęcki. The network helps show where Marek Wardęcki may publish in the future.
Co-authorship network of co-authors of Marek Wardęcki
This figure shows the co-authorship network connecting the top 25 collaborators of Marek Wardęcki. A scholar is included among the top collaborators of Marek Wardęcki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marek Wardęcki. Marek Wardęcki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cella, David, Quentin A. Hill, Frank Shafer, et al.. (2025). FACIT-Fatigue scale in patients with cold agglutinin disease: psychometric validation and estimation of clinically meaningful change. SHILAP Revista de lepidopterología. 4.
2.
Röth, Alexander, Catherine M. Broome, Wilma Barcellini, et al.. (2024). Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension. EClinicalMedicine. 74. 102732–102732.
3.
Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, et al.. (2024). Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B. EClinicalMedicine. 74. 102733–102733.
4.
Röth, Alexander, Catherine M. Broome, Wilma Barcellini, et al.. (2023). Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up. Blood Advances. 7(19). 5890–5897.
5.
D’Sa, Shirley, Josephine M. I. Vos, Wilma Barcellini, et al.. (2023). Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study. Blood. 142(Supplement 1). 1069–1069.
6.
Röth, Alexander, Wilma Barcellini, Shirley D’Sa, et al.. (2023). Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease. American Journal of Hematology. 98(8). 1246–1253.
7.
D’Sa, Shirley, Josephine M. I. Vos, Wilma Barcellini, et al.. (2023). Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study. Blood. 143(8). 713–720.
8.
Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, et al.. (2023). P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY. HemaSphere. 7(S3). e83270db–e83270db.
9.
Röth, Alexander, Sigbjørn Berentsen, Wilma Barcellini, et al.. (2022). Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood. 140(9). 980–991.
10.
Röth, Alexander, Catherine M. Broome, Wilma Barcellini, et al.. (2022). Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study. European Journal Of Haematology. 110(3). 280–288.
11.
Kosinski, Mark, et al.. (2021). Clinically Important Change in SF-12v2 Physical (PCS) and Mental (MCS) Component Summary Scores for Patients with Cold Agglutinin Disease: An Analysis Using the Phase 3 CARDINAL and CADENZA Studies. Blood. 138(Supplement 1). 2002–2002.
12.
Berentsen, Sigbjørn, Wilma Barcellini, Shirley D’Sa, et al.. (2021). Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study. Blood. 138(Supplement 1). 349–349.
13.
Garg, Satish K., Karin Wernicke‐Panten, Marek Wardęcki, et al.. (2020). Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technology & Therapeutics. 22(7). 516–526.
14.
Garg, Satish K., Karin Wernicke‐Panten, Marek Wardęcki, et al.. (2019). Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technology & Therapeutics. 22(2). 85–95.
15.
Bolli, Geremia B., Matthew C. Riddle, Richard M. Bergenstal, et al.. (2017). Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial. Diabetes & Metabolism. 43(4). 351–358.
16.
Rosenstock, Julio, Bruno Guerci, M Hanefeld, et al.. (2016). Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. Diabetes Care. 39(8). 1318–1328.
17.
Riddle, Matthew C., Geremia B. Bolli, Philip Home, et al.. (2016). Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes. Diabetes Technology & Therapeutics. 18(4). 252–257.
18.
Yki-Järvinen, H, Richard M. Bergenstal, Geremia B. Bolli, et al.. (2015). Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12‐month trial including 6‐month extension. Diabetes Obesity and Metabolism. 17(12). 1142–1149.
19.
Yki‐Järvinen, Hannele, Richard M. Bergenstal, M. Ziemen, et al.. (2014). New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2). Diabetes Care. 37(12). 3235–3243.
20.
Rabasa‐Lhoret, Rémi, Matthew C. Riddle, Geremia B. Bolli, et al.. (2014). New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs. Fixed Dosing Intervals in People with T2DM. Canadian Journal of Diabetes. 38(5). S53–S53.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Anna Zaremba Breakdown of academic impact, for papers by Laura Guazzarotti Breakdown of academic impact, for papers by Kuralay Atageldiyeva Breakdown of academic impact, for papers by B. Augendre‐Ferrante Breakdown of academic impact, for papers by C. S. Paththinige Breakdown of academic impact, for papers by Aldo Del Col Breakdown of academic impact, for papers by Blaž Krhin Breakdown of academic impact, for papers by Richard Dolinar Breakdown of academic impact, for papers by Heinrich Kahles Breakdown of academic impact, for papers by Jeanne E. O’Brien